Neil P. Shah, Dong-Wook Kim, Hagop Kantarjian, Philippe Rousselot, Pedro Enrique Dorlhiac Llacer, Alicia Enrico, Jorge Vela-Ojeda, Richard T. Silver, Hanna Jean Khoury, Martin C. Müller, Alexandre Lambert, Yousif Matloub, and Andreas Hochhaus. 2010. “Potent, Transient Inhibition of BCR-ABL With Dasatinib 100 Mg Daily Achieves Rapid and Durable Cytogenetic Responses and High Transformation-Free Survival Rates in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance, Suboptimal Response or Intolerance to Imatinib”. Haematologica 95 (2). Pavia, Italy, 232-40.